

Additional file 1

Table S1. Clinical characteristics of healthy control, treatment-naïve chronically HBV-infected patients.

Group	HC	eAg+CI ⁺ nf	eAg+CHep	eAg-CI ⁺ nf	eAg-CHep	Ungrouped
Number	25	31	28	30	7	10
Gender (male/female)	10/14	18/13	21/7	28/2	5/2	4/6
Age (years) *	25(19-41)	26.5(19-47)	30(21-42)	35.5(19-54)	40.5(39-42)	29(22-56)
ALT (IU/L) *	19(15-74)	31(11-43)	136.5(84-505)	25(13-56)	119(86-950)	46.5(20-64)
HBV DNA (log ₁₀ IU/mL) *	NA	7.94(6.91-8.62)	7.49(5.74-9.03)	2.42(2-3.77)	5.83(3.1-7.27)	6.29(3.2-8.4)
HBsAg (IU/mL) *	NA	36673(894.5-52000)	18042(1494-52000)	1108.5(3.6-5976)	2560.7(283.3-7141.4)	2791(655.5-52000)
HBeAg/anti-HBe	NA	31/0	27/0	0/28	0/6	10/4

*Data are shown as median (range); ALT, alanine aminotransferase; anti-HBe, antibody to hepatitis B e antigen; eAg⁺CHep, HBeAg-positive chronic hepatitis B; eAg⁺CI⁺nf, HBeAg-positive chronic HBV infection; eAg⁻CHep, HBeAg-negative chronic hepatitis B; eAg⁻CI⁺nf, HBeAg-negative chronic HBV infection; HC, healthy control; NA, not available. Fig. 2, available data from 25 HC, 24 eAg⁺CI⁺nf, 21 eAg⁺CHep, 26 eAg⁻CI⁺nf and 7 eAg⁻CHep patients; Fig. 3, available data from 33 chronically HBV-infected patients.